Omnicell (NASDAQ:OMCL) Shares Cross Above 200-Day Moving Average – Time to Sell?

Omnicell, Inc. (NASDAQ:OMCL) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $35.73 and traded as high as $51.14. Omnicell shares last traded at $50.30, with a volume of 270,997 shares traded.

Wall Street Analyst Weigh In

OMCL has been the subject of several recent analyst reports. Benchmark lifted their price target on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. UBS Group set a $53.00 target price on Omnicell in a research note on Friday, January 16th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Wells Fargo & Company raised their price target on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Finally, KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research note on Wednesday, January 7th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus target price of $48.57.

Omnicell Price Performance

The stock has a 50 day moving average of $44.06 and a 200-day moving average of $35.73. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. The company has a market cap of $2.26 billion, a PE ratio of 116.98, a price-to-earnings-growth ratio of 5.47 and a beta of 0.77.

Insider Activity

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. Dimensional Fund Advisors LP increased its stake in shares of Omnicell by 9.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after acquiring an additional 197,462 shares during the period. Lazard Asset Management LLC grew its position in Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after purchasing an additional 62,733 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after buying an additional 17,680 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock valued at $35,163,000 after buying an additional 30,678 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Omnicell in the third quarter worth about $25,625,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.